- Home
- FNLC vs NGNE Comparison
FNLC vs NGNE Comparison
Compare FNLC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- NGNE
- Stock Information
- Founded
- FNLC 1864
- NGNE 2003
- Country
- FNLC United States
- NGNE United States
- Employees
- FNLC N/A
- NGNE N/A
- Industry
- FNLC Major Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- NGNE Health Care
- Exchange
- FNLC Nasdaq
- NGNE Nasdaq
- Market Cap
- FNLC 303.4M
- NGNE 325.3M
- IPO Year
- FNLC 1999
- NGNE N/A
- Fundamental
- Price
- FNLC $26.79
- NGNE $18.16
- Analyst Decision
- FNLC
- NGNE Strong Buy
- Analyst Count
- FNLC 0
- NGNE 7
- Target Price
- FNLC N/A
- NGNE $41.86
- AVG Volume (30 Days)
- FNLC 15.7K
- NGNE 133.6K
- Earning Date
- FNLC 10-22-2025
- NGNE 11-14-2025
- Dividend Yield
- FNLC 5.52%
- NGNE N/A
- EPS Growth
- FNLC 13.09
- NGNE N/A
- EPS
- FNLC 2.68
- NGNE N/A
- Revenue
- FNLC $85,448,000.00
- NGNE N/A
- Revenue This Year
- FNLC N/A
- NGNE N/A
- Revenue Next Year
- FNLC N/A
- NGNE N/A
- P/E Ratio
- FNLC $9.86
- NGNE N/A
- Revenue Growth
- FNLC 10.86
- NGNE N/A
- 52 Week Low
- FNLC $22.11
- NGNE $6.88
- 52 Week High
- FNLC $31.05
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- FNLC 51.58
- NGNE 43.10
- Support Level
- FNLC $26.32
- NGNE $17.13
- Resistance Level
- FNLC $27.32
- NGNE $18.40
- Average True Range (ATR)
- FNLC 0.44
- NGNE 1.24
- MACD
- FNLC -0.10
- NGNE -0.13
- Stochastic Oscillator
- FNLC 36.72
- NGNE 31.65
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.